会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 8. 发明申请
    • SUBSTITUTED PYRAZOLE COMPOUNDS
    • 取代的吡唑化合物
    • US20110275610A1
    • 2011-11-10
    • US13145728
    • 2010-01-22
    • Alaric J. DyckmanWilliam J. PittsScott Hunter Watterson
    • Alaric J. DyckmanWilliam J. PittsScott Hunter Watterson
    • A61K31/4245A61P29/00A61P37/00C07D413/14
    • C07D413/14
    • Disclosed are compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein: n is zero or an integer selected from 1 through 4; R1 is cycloalkyl, aryl, heteroaryl, or heterocyclyl, each optionally substituted with one to five substituents independently selected from C1 to C6 alkyl, C1 to C4 haloalkyl, benzyl, —OR4, and/or halogen; and R2, R3, R4, and n are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
    • 公开了式(I)的化合物或其药学上可接受的盐,其中:n为0或选自1至4的整数; R 1是环烷基,芳基,杂芳基或杂环基,各自任选地被一至五个独立地选自C 1至C 6烷基,C 1至C 4卤代烷基,苄基,-OR 4和/或卤素的取代基取代。 并且R 2,R 3,R 4和n在本文中定义。 还公开了使用这种化合物作为G蛋白偶联受体S1P1的选择性激动剂的方法,以及包含这些化合物的药物组合物。 这些化合物可用于治疗,预防或减缓各种治疗领域(例如自身免疫疾病和血管疾病)中的疾病或病症的进展。
    • 9. 发明授权
    • Substituted pyrazole compounds
    • 取代的吡唑化合物
    • US08389509B2
    • 2013-03-05
    • US13145728
    • 2010-01-22
    • Alaric J. DyckmanWilliam J. PittsScott Hunter Watterson
    • Alaric J. DyckmanWilliam J. PittsScott Hunter Watterson
    • A61K31/4155A61K31/397A61K31/4245C07D231/10C07D271/06C07D205/04
    • C07D413/14
    • Disclosed are compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein: n is zero or an integer selected from 1 through 4; R1 is cycloalkyl, aryl, heteroaryl, or heterocyclyl, each optionally substituted with one to five substituents independently selected from C1 to C6 alkyl, C1 to C4 haloalkyl, benzyl, —OR4, and/or halogen; and R2, R3, R4, and n are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
    • 公开了式(I)的化合物或其药学上可接受的盐,其中:n为0或选自1至4的整数; R 1是环烷基,芳基,杂芳基或杂环基,各自任选地被一至五个独立地选自C 1至C 6烷基,C 1至C 4卤代烷基,苄基,-OR 4和/或卤素的取代基取代。 并且R 2,R 3,R 4和n在本文中定义。 还公开了使用这种化合物作为G蛋白偶联受体S1P1的选择性激动剂的方法,以及包含这些化合物的药物组合物。 这些化合物可用于治疗,预防或减缓各种治疗领域(例如自身免疫疾病和血管疾病)中的疾病或病症的进展。